Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Danaher reported revenue of $5.8 billion for Q1 2024, a decrease of 19.1% year-over-year, with EPS at $1.92 compared to $2.36 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $5.64 billion by 2.85%, and the EPS also surpassed the consensus estimate of $1.72 by 11.63% [1] Financial Performance Metrics - Organic sales growth was -4%, better than the estimated -6.9% [2] - Diagnostics sales reached $2.53 billion, exceeding the average estimate of $2.43 billion, reflecting a year-over-year increase of 6.4% [2] - Life Sciences sales were $1.75 billion, slightly above the estimated $1.72 billion, marking a 2.1% year-over-year increase [2] - Biotechnology sales totaled $1.52 billion, surpassing the average estimate of $1.49 billion [2] - Operating profit for Life Sciences was $235 million, below the estimated $288.47 million [2] - Operating profit for Biotechnology was $325 million, also below the estimated $350.46 million [2] - Operating profit for Diagnostics was $830 million, significantly above the average estimate of $651.02 million [2] - The "Other" segment reported an operating loss of $78 million, worse than the estimated loss of $71.44 million [2] Stock Performance - Danaher's shares have returned -4.7% over the past month, compared to a -4.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]